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Background: The Global initiative for chronic Obstructive Lung Disease strategy document 
for COPD recommends treatment changes according to the persistence of symptoms or exac-
erbations. This study assessed the feasibility and outcomes of a structured step-up/step-down 
treatment approach in a randomized controlled clinical trial setting.
Methods: Japanese patients with moderate-to-severe COPD were randomized to blinded, 
double-dummy treatment with twice-daily fluticasone propionate/salmeterol (FP/SAL) 
250/50 µg or once-daily tiotropium bromide (TIO) 18 µg for 24 weeks (dual bronchodilator 
was not available). At 4-weekly intervals, patients remaining symptomatic (COPD Assessment 
Test score .10) or experiencing an exacerbation were offered the option to use triple therapy. 
Primary endpoint was the proportion of patients remaining on randomized therapy. 
Results: In total, 406 patients participated (mean FEV
1
 59%±13% predicted; COPD Assessment 
Test 12±6). Of these, 204 and 201 patients were included in the FP/SAL and TIO groups, respec-
tively, of whom 67% and 63% continued treatment throughout the study; this difference was not 
statistically significant. Time to first therapy switch was longer with FP/SAL, but not significantly 
(P=0.21). More patients in Global initiative for chronic Obstructive Lung Disease (2011 criteria) 
groups C/D switched (FP/SAL 55%, TIO 63%) than in groups A/B (FP/SAL 27%, TIO 27%). 
Conclusion: Given the choice, patients with more symptoms or those experiencing an exac-
erbation will agree to step-up therapy. Effectiveness of disease management pathways can be 
tested using double-blind studies.
Keywords: COPD management, fluticasone propionate/salmeterol, tiotropium
Introduction
COPD is a disease characterized by chronic airflow limitation and airways inflamma-
tion, and remains a major health care problem.1 While there is no cure for COPD, it is 
preventable and treatable by reducing the impact of symptoms, such as cough, sputum 
production, and dyspnea, and reducing the risk of exacerbations.1
Guidelines, including the Global initiative for chronic Obstructive Lung Disease 
(GOLD) strategy and national guidelines, suggest a stepped approach to pharmacologic 
management of COPD following treatment algorithms or pathways in which treatment 
is changed according to the patient’s needs.1–3 For example, the 2017 GOLD strategy 
describes treatment pathways that entail treatment intensification by combining different 
classes of agents; however, these recommendations are not accompanied by guidance as 
to when these new treatments should be added.1 The guidelines suggest that treatment 
should be stepped up if the patient has “persisting symptoms” or “further exacerba-
tions”, but do not define what constitutes either of these clinical states. Similarly, other 
guidelines, such as those of the Japanese Respiratory Society, suggest a progressive 
addition of treatment, again without specific guidance as to when to step up treatment.2 
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Very few studies have tested stepping up (or stepping down) 
treatment, although one exception is the WISDOM study that 
was designed to test withdrawal of inhaled corticosteroids 
(ICS).4 Another issue is that most trials are parallel-group 
comparisons in which the treatment is determined by the 
randomization process rather than by the treating physician.
The majority of clinical studies used to inform guidelines 
are efficacy trials designed to test the benefit of one treatment 
compared with another under standardized conditions. Also, 
guidelines need to be informed by trials that test treatment 
pathways that allow the patient and physician to exercise 
treatment choices, and reflect routine practice more closely.
This study, COPD Symptom-based Management to Opti-
mize Treatment Strategy in Japan (COSMOS-J), was conducted 
to evaluate the feasibility of a randomized controlled trial 
(RCT) designed to test a symptom-based pharmacological 
treatment pathway using a step-up (step-down) to (from) triple 
therapy. The study was conducted in Japanese patients with 
moderate-to-severe COPD using a unique protocol, which was 
based on monthly assessment of symptoms using the COPD 
Assessment Test (CAT) and monitoring the occurrence of 
exacerbations since the previous study visit. The treatment 
approach was consistent with the Japanese licenses for the 
drugs used and the Japanese Respiratory Society guidelines 
at the time of protocol development.2 It was also consistent 
with Japanese clinical practice that requires the patient to 
request maintenance treatment from their physician, since a 
repeat-prescription service is not available. When the study 
was designed (October 2012), dual bronchodilators were not 
available in Japan; therefore, a long-acting muscarinic antago-
nist (LAMA) and the combination ICS/long-acting β
2
-agonist 
(LABA) were used as randomized therapy, with the possibility 
to step up to triple therapy (ICS/LABA/LAMA). The rationale 
for these choices was that LAMA and ICS/LABA both improve 
St George’s Respiratory Questionnaire (SGRQ) scores,5,6 and 
triple therapy has been associated with improvements in out-
comes such as exacerbations and health status, whether LAMA 
is added to ICS/LABA or vice versa.7–13 Triple therapy has also 
been shown to be associated with lower all-cause mortality 
and oral corticosteroid bursts compared with ICS/LABA.14
Some of the results of this study have been previously 
reported in abstract form.15
Methods
This was a 24-week, multicenter, randomized, blinded, double-
dummy study performed in Japan (GSK study number: 
SCO116717; ClinicalTrials.gov identifier: NCT01762800). 
The study was conducted in accordance with International 
Conference on Harmonisation-Good Clinical Practice  and 
the Declaration of Helsinki (2008). All patients provided 
written informed consent prior to participation in the study. 
The ethics and review boards of all participating institutions 
approved the protocol prior to commencement of the study 
(Table S1). Anonymized individual participant data and 
study documents can be requested for further research from 
www.clinicalstudydatarequest.com.
Patients
Patients aged 40–80 years with an established clinical 
history of COPD defined by the GOLD 2011 criteria,16 a 
current or former smoking history of .10 pack-years, a 
post-bronchodilator FEV
1
 of $30% but #80% of predicted 
normal values, a post-bronchodilator FEV
1
/FVC ratio 
of ,70% and a grade of $1 on the modified Medical 
Research Council (mMRC) scale were included. Exclusion 
criteria for entry into the study included a medical diagnosis 
of predominant asthma or a respiratory disorder other than 
COPD that might interfere with the study, lung transplanta-
tion and/or lung volume reduction, and a requirement for 
regular or long-term oxygen therapy ($12 hours a day). 
Patients were classified into one of the four GOLD groups 
(A−D), using the GOLD 2011 criteria, based on history of 
exacerbations, airflow limitation, and CAT score.
study protocol
The full protocol has been published.17 After a 4-week 
run-in period during which patients remained on their usual 
treatment for COPD, patients were randomized to receive 
fluticasone propionate/salmeterol combination (FP/SAL; 
Adoair™ GlaxoSmithKline, Brentford, UK) 250/50 µg 
twice daily delivered via the DISKUS™ (GlaxoSmithKline) 
inhalation device (“FP/SAL-single”), or tiotropium bro-
mide (TIO; SPIRIVA™ [Boehringer Ingelheim, Ingelheim, 
German]) 18 µg delivered once daily via the Handihaler™ 
inhalation device (“TIO-single”) for 24 weeks. These are 
the licensed doses for these medicines in Japan. Random-
ized treatments were given blinded and double dummy, so 
patients in both groups also received placebo medication 
via a matched-placebo inhalation device (Figure 1). Those 
patients who stepped up were therefore unblinded, in that 
they knew that they were receiving both treatments, but they 
remained blind to their randomized therapy. Patients who 
were subsequently treated with triple therapy could receive 
additional non-trial medication, at their physician’s discretion.
After randomization, patients were reviewed every 
4 weeks to assess their symptom level and the occurrence of 
any exacerbations (Figure 1). If they remained symptomatic, 
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randomized trial of symptom-based management in COPD
they were offered the option to step up from randomized 
treatment to triple therapy. The strength of the recom-
mendation to step up was based on predefined CAT scores 
as follows: CAT score ,10, “Your score suggests you are 
doing well. Are you satisfied with your current treatment?”; 
CAT score $10 but #15, “Your score suggests your chest 
trouble is causing you some problems because of [highest 
scoring CAT item(s)]. Are you satisfied with your current 
treatment?”; and CAT score .15, “Your score clearly sug-
gests your chest problem is having a big effect on you. We 
have an option to increase treatment. Do you want to try it?”.
Patients were also allowed to step down from triple to 
randomized treatment.17 The procedure for stepping down 
was based on the judgment of the treating physician and not 
specified in the protocol. This was largely due to the fact that 
the study would have been underpowered, for the number of 
patients who might be stepped down after previous step-up 
was unknown. In addition, the study duration would have 
allowed only a limited and very variable time for follow-up 
of patients following treatment step-down.
assessments
The primary endpoint was the proportion of patients who 
remained on randomized therapy throughout the study. 
Reported exacerbations and CAT scores were captured at 
each visit to inform physician and patient choices. Unreported 
COPD exacerbations were identified using the Exacerbations 
of COPD Tool (EXACT) diary.19 COPD symptoms were 
measured using EXACT-Respiratory Symptoms (E-RS) 
scores collected from the EXACT diary.20 The physicians did 
not use the EXACT diaries in their assessment. The propor-
tion of patients who remained on randomized therapy and 
the proportion of patients who stepped down according to 
predefined criteria were recorded. For the subgroup analysis, 
patients were categorized using the GOLD 2011 assessment 
scheme, with the CAT score as the cut point for low and 
high symptoms.
Safety was measured by recording any adverse events 
(AEs) and COPD exacerbations.
statistical analysis
It was assumed that the switch rate would be between 10% 
and 60%. Using a planned sample size of 400 patients, a 
15% difference would be detectable with 86%–99% power 
by a log-rank test. The proportion of patients remaining on 
randomized therapy was estimated using a binomial distribu-
tion, and the time to switch to triple therapy was tested using 
Kaplan–Meier plots with log-rank tests.
To investigate factors that influenced the switch to triple 
therapy, univariate and multiple logistic regression analyses 
were conducted using the following covariates: randomized 
therapy, GOLD 2011 group, sex, age, baseline RS-subscale 
scores, and eosinophil category.
Results
Of the 570 patients screened, 406 were randomized 
(Figure 2). One patient in the TIO group did not receive ran-
domized medication, and so the analysis was performed on 
the modified intent-to-treat population (TIO: n=201; FP/SAL: 
n=204; Figure 2). The reasons for patient discontinuation 
are shown in Figure 2. Very few patients withdrew during 
the study period with 366 (90.1%) patients remaining in the 
study. The main reason for withdrawal was experiencing 
an AE. Patient baseline characteristics are shown in Table 1; 
Figure 1 study design.
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the mean CAT score was 12±6, and 29% of patients in the 
TIO group and 35% in the FP/SAL group had an mMRC 
score $2 (Table 2). The proportions of patients split by 
GOLD A–D classification were similar between the treat-
ment groups, although the proportion of patients classified as 
GOLD B was slightly higher, and GOLD D slightly lower, in 
the FP/SAL vs the TIO group (Table 1). Regarding smoking 
history, 40% were current smokers in both groups. The 
COPD type in most patients was characterized clinically as 
emphysema (Table 1). A total of 156 patients (74% of those 
210 patients in whom a value was recorded at baseline) has 
an eosinophil count $2%.
Primary outcome
The number of patients in the FP/SAL group who continued 
their treatment was 136 (67%) compared with 126 (63%) 
patients in the TIO group; there was no statistically significant 
difference between the treatment groups. More than 10% of 
patients stepped up to triple therapy at the first assessment 
and thereafter there was progressive recruitment to triple 
therapy. The time to first switch to triple therapy was longer 
in the FP/SAL group compared with the TIO group, but this 
was not significant (log-rank test; P=0.214; Figure 3). Simi-
larly, the odds ratio for a treatment effect was not statistically 
significant in both the univariate and multivariable analyses 
(Table 2). In both univariate and multivariable analyses, 
patients in GOLD groups C and D were significantly 
more likely to switch than those in GOLD groups A and B 
(Figure 4; Table 2). In univariate analyses, women, patients 
aged .65 years, and patients with higher baseline E-RS 
scores (Table 2) appeared to be more likely to step up. In mul-
tivariable analysis, patients in GOLD groups C and D were 
more likely to step up than patients in GOLD groups A and B; 
in addition, older age and worse E-RS chest symptoms were 
all significantly associated with increased likelihood to switch 
to triple therapy, (Table 2). Most patients (.90%) switched 
owing to lack of efficacy. Three patients switched back from 
triple to their randomized treatment.
CaT score
In patients who did not switch, there was a general trend 
for improvement (Figure S1), but this was less obvious in 
Figure 2 Consort diagram.
Note: mITT: one patient was removed from the TIO group for not receiving study medication.
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randomized trial of symptom-based management in COPD
those who switched. When viewing this figure, it is important 
to remember that higher CAT scores were one reason for 
switching to triple therapy and that this occurred at different 
times during the study.
e-rs scores
There was a large difference in E-RS total score through-
out the study, between patients who remained on randomized 
therapy and those who switched to triple therapy (Figure 5). 








Mean ± sD 68±7.12 68.6±6.93 68.3±7.02
age group (years), n (%)
40–49 6 (3) 3 (1) 9 (2)
50–59 14 (7) 16 (8) 30 (7)
60–69 89 (44) 83 (41) 172 (42)
70–79 88 (44) 99 (49) 187 (46)
$80 4 (2) 3 (1) 7 (2)
sex, n (%)
Male 193 (96) 192 (94) 385 (95)
history of smoking, n (%)
Current smoker 81 (40) 82 (40) 163 (40)
Former smoker 119 (59) 122 (60) 241 (60)
Total pack-years
Mean ± sD 54.53±27.7 60.75±33.0 57.67±30.7
Duration of COPD (years)
Mean ± sD 3.7±3.9 3.7±4.4 3.7±4.2
COPD type, n (%)
Chronic bronchitis 26 (13) 29 (14) 55 (14)
emphysema 164 (82) 169 (83) 333 (82)
Mixed 11 (5) 6 (3) 17 (4)
asthma overlap (current), n (%)
Yes 38 (19) 41 (20) 79 (20)
mMrC grade by investigator, n (%)
1 142 (71) 132 (65) 274 (68)
2 45 (22) 60 (29) 105 (26)
3 14 (7) 12 (6) 26 (6)
4 0 0 0
FeV1/FVC (%)
a
Mean ± sD 51.4±11.4 52.6±11.1 52.0±11.3
CaT total score at screening
Mean ± sD 12±6 12±6 12±6
CaT total score category, n (%)
#9 71 (35) 70 (34) 141 (35)
10–15 76 (38) 85 (42) 161 (40)
$16 54 (27) 49 (24) 103 (25)
Predicted FeV1 (%)
a
Mean ± sD 57.8±13.7 59.5±13.0 58.7±13.3
number of exacerbations within 12 months, n (%)
0 185 (92) 192 (94) 377 (93)
$1 16 (8) 12 (6) 28 (7)
gOlD patient group, n (%)
a 59 (29) 57 (28) 116 (29)
B 83 (41) 100 (49) 183 (45)
C 12 (6) 13 (6) 25 (6)
D 47 (23) 34 (17) 81 (20)
Note: aPost bronchodilator.
Abbreviations: CAT, COPD Assessment Test; FP/SAL, fluticasone propionate/salmeterol; GOLD, Global initiative for chronic Obstructive Lung Disease 2011 criteria; 
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This difference was driven by differences in breathless-
ness and chest symptoms, rather than cough and sputum. 
There was a general trend for improvement across the 
study period that appeared to be greater in the patients who 
switched to triple therapy. Analysis of E-RS total scores by 
baseline blood eosinophil levels showed little difference in 
scores between patients with high blood eosinophil counts 
($2%) compared with low blood eosinophil counts (,2%; 
Figure S2). However, it should be noted that the relatively 
small numbers of patients in each subgroup, coupled with the 
low exacerbation rate, preclude any conclusive interpreta-
tions from these data.
Time to first exacerbation
There were very few moderate-to-severe (ie, reported) exac-
erbations in the patients who did not switch, but in those 
who stepped up to triple therapy, approximately 20% had an 
exacerbation by 24 weeks (Figure 6A). In contrast, .30% 
of patients had at least one unreported exacerbation detected 
by the EXACT, even if they did not switch (Figure 6B). The 
Kaplan–Meier curves showed different patterns between 
treatment groups; the lowest incidence of EXACT events 
(32 patients) was seen in patients randomized to FP/SAL 
who did not switch. The highest incidence of EXACT events 
(57 patients) was seen in those patients randomized to TIO 
who then switched to triple therapy (Figure 6B).
safety
All treatments were well tolerated with AEs of any degree 
of severity reported by 52% (TIO-single), 71% (TIO-triple), 
65% (FP/SAL-single), and 66% (FP/SAL-triple) of patients. 
Nasopharyngitis was the most commonly reported event 
in all groups (Table S2). None of the patients who were 
randomized to TIO and did not switch to triple therapy had 
an episode of pneumonia; pneumonia was reported in 2% 
of those randomized to, and remaining on, FP/SAL and 
Table 2 Univariate and multivariable analyses (logistic regression) of factors responsible for switch to triple therapy




switch to TrIPle randomized treatment: FP/sal vs TIO 0.840 0.559 1.263
gOlD patient category 1: C and D vs a and B 4.011 2.520 6.383
gOlD patient category 2: B and D vs a and C 1.790 1.145 2.796
eosinophil: $2% vs ,2% 0.756 0.395 1.445
sex: female vs male 2.907 1.160 7.287
age: 65–74 vs 18–64 years 3.181 1.774 5.706
age: $75 vs 18–64 years 4.081 2.030 8.205
smoking history: current smoker vs former smoker 0.751 0.493 1.144
rs-subscale breathlessness: mean baseline 1.229 1.152 1.311
rs-subscale cough and sputum: mean baseline 1.213 1.067 1.379
rs-subscale chest symptoms: mean baseline 1.399 1.242 1.575
Multivariable analysis
switch to TrIPle randomized treatment (FP/sal vs TIO) 0.952 0.603 1.504
gOlD group (C and D vs a and B) 3.362 2.047 5.523
age 65–74 vs 18–64 years 2.862 1.539 5.323
age $75 vs 18–64 years 3.141 1.485 6.643
rs-subscale chest symptoms (baseline) 1.371 1.208 1.555
Abbreviations: FP/SAL, fluticasone propionate/salmeterol; GOLD, Global initiative for chronic Obstructive Lung Disease 2011 criteria; RS, respiratory symptoms; 
TIO, tiotropium.
Figure 3 Kaplan–Meier curves of time to switch to triple therapy.
Note: Difference in the time course between the treatment arms was not statistically 
significant.
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randomized trial of symptom-based management in COPD
4%–8% of those who switched to triple. Two serious cases 
(ie, requiring hospitalization) of pneumonia occurred in each 
of the groups that received ICS.
Discussion
This study used an innovative trial design that allowed 
patients and physicians to decide whether to change treat-
ment. In both treatment arms, patients could have their 
therapy stepped up, in this case by switching to triple therapy 
if the current treatment was considered to be insufficient. 
Although the physicians were given guidance about asking 
the patients whether they wished to step up, it remained the 
patients’ choice. Persistence in symptoms, as measured by 
the CAT, or the occurrence of an exacerbation since the last 
visit, was the reason for switching therapy. The primary end-
point, the number of patients who remained on randomized 
treatment with either FP/SAL or TIO, showed that 67% 
of patients continued in the FP/SAL group compared with 
63% of patients in the TIO group. Although the time to first 
switch to triple therapy was longer in patients randomized 
to FP/SAL, it was not significant.
There was an overall trend for patients with more severe 
COPD to step up their therapy, as evidenced by higher 
baseline symptoms and a greater risk of exacerbations. 
This suggests that the physicians followed the step-up 
protocol and the patients responded to the physicians’ sug-
gestions about stepping up therapy. The study protocol did 
not require baseline risk to be an indication for switching 
therapy, but patients at greater risk of exacerbations (GOLD 
2011 groups C and D) were more likely to be stepped up to 
triple therapy during the study – either because of persisting 
symptoms or the occurrence of an exacerbation. The slightly 
Figure 4 analysis of the proportion of patients who continued receiving their randomized treatment in (A) gOlD group a; (B) gOlD group B; (C) gOlD group C; 
(D) gOlD group D.
Note: Figures in parentheses represent 95% CIs.
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Figure 5 summary of rs median scores: (A) rs total, (B) rs breathlessness, (C) rs cough and sputum, and (D) rs chest symptoms.
Abbreviations: FP/SAL, fluticasone propionate/salmeterol; RS, respiratory symptoms; TIO, tiotropium.
higher proportion of patients classified as GOLD group D in 
the TIO vs the FP/SAL group at baseline should be consid-
ered when comparing outcomes between treatment groups. 
Step-up due to an exacerbation was only suggested if the 
patient reported a moderate–severe exacerbation; however, 
the rate of reported exacerbations was very low, so oppor-
tunities for step-up were limited. Similarly, the patients 
generally had low CAT scores compared with those reported 
in primary care in Europe,21 which again may have reduced 
the likelihood of a switch. However, despite the relatively 
mild severity of the patients’ COPD, the results suggest 
that patient management pathways in which patients and 
physicians make the treatment decisions can be tested in a 
randomized blinded controlled trial setting. This approach 
avoids some of the biases associated with retrospective 
real-world database studies, particularly confounding by 
severity. The study also shows that patients with more symp-
toms or impaired health status will take the offer of treatment 
step-up, which is, in itself, an important observation.
One defining characteristic of the study was that very few 
patients dropped out; 90% of the patients remained in the 
study until the end. This may be due to the use of a flexible 
treatment that more closely reflects clinical practice, ie, it 
allows for treatment intensification if the patient’s condition 
worsens. In conventional efficacy RCTs, the patient may 
withdraw from the study in order to step up treatment, which 
therefore introduces a “healthy survivor” bias.
The study can be criticized for encouraging a more 
aggressive treatment approach than that seen in routine 
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randomized trial of symptom-based management in COPD
Figure 6 Kaplan–Meier curves of time to the first exacerbation defined by (A) physician’s diagnosis and (B) eXaCT.
Note: Differences in the time course between treatment arms were not statistically significant.
Abbreviations: EXACT, Exacerbations of COPD Tool; FP/SAL, fluticasone propionate/salmeterol; TIO, tiotropium.
approach to treatment, rather than routinely enquiring about 
patients’ satisfaction with current treatment and offering 
step-up. In support of this suggestion, a UK retrospective 
database study showed that although patients were progres-
sively stepped up to triple therapy (usually adding LAMA 
to ICS/LABA), this took a number of years.22 Furthermore, 
the study shows that if physicians take a clinical evidence-
based approach to increasing treatment, they appear to make 
appropriate decisions, since the patients who had treatment 
intensification were more symptomatic and at greater risk of 
exacerbations. This supports an observation from a retrospec-
tive study in a well-characterized cohort of Japanese patients 
with COPD, which showed that over half of the patients 
on triple therapy had their treatment intensified because of 
unsatisfactory improvement in symptoms when receiving 
their previous therapy.23 The period and size of the study were 
too short to allow a formal test of step-up approaches in terms 
of outcomes such as exacerbation rate and improvements 
in health status, but it does show that RCTs, needed to test 
treatment algorithms, are feasible. In addition, the study did 
not assess structured approaches to stepping down treatment. 
The study was designed and performed before the WISDOM 
study on ICS withdrawal was reported4 and before GOLD 
suggestions that step-down could be considered; therefore, 
the focus was on step-up criteria. The 24-week study dura-
tion would allow little opportunity to study step-down from 
previous step-up, and further studies of longer duration are 
required to address this topic.
The choice of treatments for this study merits some dis-
cussion. This study tested an innovative methodology that 
attempted to model clinical practice in combination with 
the rigor of a clinical trial. The study was designed with 
the current Japanese COPD management pathway in mind; 
however, new trial data emerge and guidelines and treatment 
recommendations change, so all such trials become hostage to 
new developments. Although the GOLD strategy document 
suggests reserving ICS-containing treatments for patients 
at higher risk of exacerbations,1 other guidelines, such as 
the Japanese Respiratory Society guidelines,2 do not make 
that distinction. They recommend ICS/LABA as part of a 
treatment intensification approach in response to worsening 
symptoms and exercise performance as well as exacerba-
tions. Adding an ICS to a LABA has symptomatic benefits;24 
addition of ICS/LABA improved symptoms and health status 
when added to LAMA7 and conversely adding LAMA to 
ICS/LABA.11,25 The use of triple therapy is increasing,22 and 
although not all of it will be appropriate, some will be a suit-
able response by physicians to their patients’ symptomatic 
needs. The choice of treatments for this study should also 
be set in historical context. At the time it was designed, 
dual bronchodilators were not available in Japan. Although 
there is evidence that LAMA/LABA and ICS/LABA have 
similar efficacy in terms of improvement in SGRQ score,26,27 
risk–benefit considerations would now indicate use of dual 
bronchodilator as step-up therapy from monotherapy for 
symptoms, reserving ICS/LABA step-up for exacerbations.
Conclusion
Efficacy trials do not usually give guidance to physicians 
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treatment. The findings from this novel trial design suggest 
that it is possible to perform a blinded treatment pathway 
RCT that minimizes bias due to the patient and physician’s 
knowledge of initial treatment allocation. Studies of this type 
could provide physicians and guideline committees with a 
stronger evidence base on which to design and apply treat-
ment pathways in COPD.
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Table S1 Institutional review boards at participating study sites
Site information Name of institutional review board
Prefecture
1 hokkaido national hospital Organization Central review Board
2 Ibaraki national hospital Organization Central review Board
3 Ibaraki Tsuchiura Kyodo general hospital IrB
4 Ibaraki Ibaraki Prefectural Central hospital IrB
5 Ibaraki review Board of human rights and ethics for Clinical studies IrB
6 Tokyo Tokyo-eki Center-building Clinic IrB
7 Tokyo suzuki Clinic Internal Medicine and Cardiology IrB
8 Tokyo showa general hospital IrB
9 Kanagawa Yasuda hospital IrB
10 Kanagawa sugiura Clinic IrB
11 niigata niigata rinko hospital IrB
12 niigata niigata City general hospital IrB
13 niigata national hospital Organization Central review Board
14 shizuoka review Board of human rights and ethics for Clinical studies IrB
15 Kyoto Japanese red Cross Kyoto Daini hospital IrB
16 Kyoto national hospital Organization Central review Board
17 Osaka Chuto hospital IrB
18 Osaka national hospital Organization Central review Board
19 nara nara hospital Kinki University Faculty of Medicine IrB
20 hyogo Terada Clinic Internal respiratory Medicine IrB
21 hiroshima national hospital Organization Central review Board
22 hiroshima Kure Kyosai hospital-hiroshima IrB
23 hiroshima Chugoku Central hospital-hiroshima IrB
24 Yamaguchi national hospital Organization Central review Board
25 Kagawa Yasuda hospital IrB
26 Kagawa KKr Takamatsu hospital IrB
27 Kagawa Takamatsu Municipal hospital IrB
28 Kochi sugiura Clinic IrB
29 Fukuoka Fukuoka University hospital IrB
30 Fukuoka sugiura Clinic IrB
31 saga saga-Ken Medical Center Koseikan IrB
32 Okinawa Chuto hospital IrB
33 Okinawa Chuto hospital IrB
34 Okinawa Okinawa Prefectural Chubu hospital IrB
35 Ibaraki Ibaraki higashi national hospital IrB
36 Osaka aMC nishi-umeda Clinic IrB
37 Tokyo aMC nishi-umeda Clinic IrB
38 Osaka Clinical research Tokyo hospital IrB
39 hiroshima hiroshima Prefectural hospital IrB
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randomized trial of symptom-based management in COPD
Figure S1 summary of CaT total score for patients who received (A) FP/sal single therapy; (B) FP/sal triple therapy; (C) TIO single therapy; and (D) TIO triple 
therapy.
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Figure S2 summary of e-rs total scores by treatment group for patients with (A) low blood eosinophil counts (,2%) and (B) high blood eosinophil counts ($2%) at baseline.
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any ae, n (%) 65 (52) 53 (71) 88 (65) 45 (66)
nasopharyngitis 19 (15) 20 (27) 25 (18) 14 (21)
Bronchitis 7 (6) 5 (7) 7 (5) 7 (10)
Oral candidiasis 0 2 (3) 3 (2) 3 (4)
Pneumonia 0 6 (8) 3 (2) 3 (4)
Drug-related events, n (%) 10 (8) 8 (11) 29 (21) 9 (13)
aes leading to withdrawal, n (%) 6 (5) 3 (4) 13 (10) 0
any sae, n (%) 8 (6) 8 (11) 8 (6) 6 (9)
Pneumonia 0 2 (3) 2 (1) 2 (3)
COPD 1 (,1) 3 (4) 1 (,1) 0
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